CTIM-33. THE REMIND TRIAL: MULTI-ANTIGEN TARGETED T CELLS FOR PEDIATRIC CNS TUMORS

BACKGROUND: Patients with relapsed CNS malignancies or DIPG face terrible prognoses. We hypothesized that T cells specific for 3 tumor-associated antigens (TAA), WT1, PRAME and survivin, would be safe and elicit anti-tumor immunity. METHODS: Patients (n=15) received autologous tumor antigen-associat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Grant, Melanie, Fortiz, Maria Fernanda, Wang, Jennifer (Lu), Lang, Haili, Datar, Anushree, Reynolds, Emily, Terpilowski, Madeline, Lazarski, Christopher, Tanna, Jay, Pitino, Adriana, Zhang, Nan, Hoq, Fahmida, Hanley, Patrick, Kilburn, Lindsay, Packer, Roger, Rood, Brian, Bollard, Catherine, Hwang, Eugene
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Trials: Immunologic
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650401/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.167
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars